| Summary: | Over the past decades, the immense clinical need for early detection methods and treatments
for dementia has become a priority worldwide. The advances in PET biomarkers play increasingly
important roles in understanding disease mechanisms by demonstrating the protein pathology
underlying dementia in the brain. Amyloid-β and tau deposition in PET images are now
key diagnostic biomarkers for the Alzheimer’s disease continuum. The inclusion of biomarkers
in the diagnostic criteria has achieved a paradigm shift in facilitating early differential diagnosis,
predicting disease prognosis, and influencing clinical management. Furthermore, in vivo
images showing pathology could become prognostic as well as surrogate biomarkers in therapeutic
trials. In this review, we focus on recent developments in radiotracers for amyloid-β and
tau PET imaging in Alzheimer’s disease and other neurodegenerative diseases. Further, we introduce
their potential application as future perspectives.
|
|---|